Literature DB >> 20495091

Vinpocetine as a potent antiinflammatory agent.

Alexandre E Medina1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20495091      PMCID： PMC2890434          DOI： 10.1073/pnas.1005138107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


× No keyword cloud information.
  21 in total

1.  Vinpocetine inhibits NF-kappaB-dependent inflammation via an IKK-dependent but PDE-independent mechanism.

Authors:  Kye-Im Jeon; Xiangbin Xu; Toru Aizawa; Jae Hyang Lim; Hirofumi Jono; Dong-Seok Kwon; Jun-Ichi Abe; Bradford C Berk; Jian-Dong Li; Chen Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-06       Impact factor: 11.205

Review 2.  Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms.

Authors:  J A Beavo
Journal:  Physiol Rev       Date:  1995-10       Impact factor: 37.312

Review 3.  The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease.

Authors:  Bruno P Imbimbo
Journal:  Expert Opin Investig Drugs       Date:  2004-11       Impact factor: 6.206

4.  Genetic analysis of immunomodulating factors in sporadic Parkinson's disease.

Authors:  R Krüger; C Hardt; F Tschentscher; S Jäckel; W Kuhn; T Müller; J Werner; D Woitalla; D Berg; N Kühnl; G A Fuchs; E J Santos; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  J Neural Transm (Vienna)       Date:  2000       Impact factor: 3.575

Review 5.  Vinpocetine for cognitive impairment and dementia.

Authors:  S Z Szatmari; P J Whitehouse
Journal:  Cochrane Database Syst Rev       Date:  2003

6.  A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction.

Authors:  R Balestreri; L Fontana; F Astengo
Journal:  J Am Geriatr Soc       Date:  1987-05       Impact factor: 5.562

Review 7.  PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.

Authors:  Katharine H Banner; Michael A Trevethick
Journal:  Trends Pharmacol Sci       Date:  2004-08       Impact factor: 14.819

8.  Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease.

Authors:  G Boka; P Anglade; D Wallach; F Javoy-Agid; Y Agid; E C Hirsch
Journal:  Neurosci Lett       Date:  1994-05-19       Impact factor: 3.046

9.  Vinpocetine enhances retrieval of a step-through passive avoidance response in rats.

Authors:  V J DeNoble
Journal:  Pharmacol Biochem Behav       Date:  1987-01       Impact factor: 3.533

10.  The impairment of long-term potentiation in rats with medial septal lesion and its restoration by cognition enhancers.

Authors:  P Molnár; L Gaál; C Horváth
Journal:  Neurobiology (Bp)       Date:  1994
View more
  19 in total

1.  Chemocentric informatics approach to drug discovery: identification and experimental validation of selective estrogen receptor modulators as ligands of 5-hydroxytryptamine-6 receptors and as potential cognition enhancers.

Authors:  Rima Hajjo; Vincent Setola; Bryan L Roth; Alexander Tropsha
Journal:  J Med Chem       Date:  2012-06-11       Impact factor: 7.446

2.  FTO-Dependent N 6-Methyladenosine Modifications Inhibit Ovarian Cancer Stem Cell Self-Renewal by Blocking cAMP Signaling.

Authors:  Hao Huang; Yinu Wang; Manoj Kandpal; Guangyuan Zhao; Horacio Cardenas; Yanrong Ji; Anusha Chaparala; Edward J Tanner; Jianjun Chen; Ramana V Davuluri; Daniela Matei
Journal:  Cancer Res       Date:  2020-06-30       Impact factor: 12.701

3.  Vinpocetine inhibits Streptococcus pneumoniae-induced upregulation of mucin MUC5AC expression via induction of MKP-1 phosphatase in the pathogenesis of otitis media.

Authors:  Ji-Yun Lee; Kensei Komatsu; Byung-Cheol Lee; Masanori Miyata; Ashley O'Neill Bohn; Haidong Xu; Chen Yan; Jian-Dong Li
Journal:  J Immunol       Date:  2015-05-13       Impact factor: 5.422

Review 4.  An update on vinpocetine: New discoveries and clinical implications.

Authors:  Yi-Shuai Zhang; Jian-Dong Li; Chen Yan
Journal:  Eur J Pharmacol       Date:  2017-11-26       Impact factor: 4.432

5.  Vinpocetine Inhibits NF-κB-Dependent Inflammation in Acute Ischemic Stroke Patients.

Authors:  Fang Zhang; Chen Yan; Changjuan Wei; Yang Yao; Xiaofeng Ma; Zhongying Gong; Shoufeng Liu; Dawei Zang; Jieli Chen; Fu-Dong Shi; Junwei Hao
Journal:  Transl Stroke Res       Date:  2017-07-09       Impact factor: 6.829

6.  Vinpocetine inhibits amyloid-beta induced activation of NF-κB, NLRP3 inflammasome and cytokine production in retinal pigment epithelial cells.

Authors:  Ruozhou Tom Liu; Aikun Wang; Eleanor To; Jiangyuan Gao; Sijia Cao; Jing Z Cui; Joanne A Matsubara
Journal:  Exp Eye Res       Date:  2014-07-17       Impact factor: 3.467

Review 7.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

Review 8.  Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.

Authors:  F Ahmad; T Murata; K Shimizu; E Degerman; D Maurice; V Manganiello
Journal:  Oral Dis       Date:  2014-09-12       Impact factor: 3.511

9.  Quantitative Determination of Vinpocetine in Dietary Supplements.

Authors:  John M T French; Matthew D King; Owen M McDougal
Journal:  Nat Prod Commun       Date:  2016-05       Impact factor: 0.986

10.  PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis.

Authors:  Sabrina Noel; Barbara Dhooghe; Teresinha Leal
Journal:  Front Pharmacol       Date:  2012-09-18       Impact factor: 5.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.